Nanobiotix Reports Monthly Update on Share Capital and Voting Rights (March 2026)

On April 7, 2026, Nanobiotix S.A. (Nasdaq: NBTX), a late-stage clinical biotechnology company, disclosed its updated share capital and voting rights as of March 31, 2026. The filing was made in accordance with the French Commercial Code and the General Regulation of the French Financial Markets Authority. As of the reporting date, the company had 48,517,630 shares outstanding. The total number of theoretical voting rights was reported as 50,165,132, while the total number of exercisable voting rights stood at 50,143,014. The discrepancy between theoretical and exercisable rights is due to shares held in treasury for which voting rights are suspended. Nanobiotix is focused on developing physics-based therapeutic approaches, including its lead nanotechnology platforms for applications in oncology and other disorders. This filing is a routine regulatory update regarding the company's capital structure and does not contain any updates on clinical trial progress or financial results.